Imunon (IMNN) pays executive chair with 7,147 shares

Rhea-AI Filing Summary

Tardugno Michael H reported acquisition or exercise transactions in this Form 4 filing.

Imunon, Inc. reporting person Michael H. Tardugno, Executive Chairman of the Board, received a grant of 7,147 shares of Common Stock on 2026-08-14. The grant was stock issued in lieu of cash for base salary, increasing his directly held position to 82,504 shares. He also reports 4,622 shares held indirectly through an IRA.

Insider Trade Summary

Net Buyer: 7,147 shares

Net Buy 2 txns

Insider Tardugno Michael H

Role Executive Chairman of Board

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	7,147	$1.65	$12K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 82,504 shares (Direct); Common Stock — 4,622 shares (Indirect, Held by IRA)

Footnotes (1)

1. F1. Stock granted in lieu of cash for base salary

Key Figures

Stock grant shares: 7,147 shares Grant valuation price: $1.65 per share Direct holdings after grant: 82,504 shares +1 more

4 metrics

Stock grant shares 7,147 shares Common Stock granted on 2026-08-14 in lieu of cash for base salary

Grant valuation price $1.65 per share Per-share value for the 7,147-share Common Stock grant

Direct holdings after grant 82,504 shares Total directly held Imunon common shares following the 2026-08-14 grant

Indirect IRA holdings 4,622 shares Imunon common shares held indirectly by Michael H. Tardugno through an IRA

Key Terms

Grant, award, or other acquisition, Held by IRA, in lieu of cash

3 terms

Grant, award, or other acquisition financial

"transaction code description is "Grant, award, or other acquisition""

Held by IRA financial

"nature_of_ownership field states "Held by IRA""

in lieu of cash financial

"footnote reads "Stock granted in lieu of cash for base salary""

FAQ

What transaction did Imunon (IMNN) insider Michael H. Tardugno report on this Form 4?

Michael H. Tardugno reported a grant of 7,147 shares of Imunon common stock on 2026-08-14, received as stock in lieu of cash for base salary, classified as a grant, award, or other acquisition.

At what price was the Imunon (IMNN) stock grant to Michael H. Tardugno valued?

The 7,147-share stock grant to Michael H. Tardugno was valued at $1.65 per share. This per-share value is shown for the grant recorded as stock in lieu of cash compensation for his base salary.

How many Imunon (IMNN) shares does Michael H. Tardugno hold after this Form 4 transaction?

After the grant, Michael H. Tardugno holds 82,504 Imunon common shares directly. He also reports an additional 4,622 shares held indirectly through an IRA, according to the holding entry in the Form 4.

Was the Imunon (IMNN) stock grant to Michael H. Tardugno part of his cash salary?

Yes. The Form 4 footnote states the 7,147-share grant was “stock granted in lieu of cash for base salary”, indicating a portion of his salary was paid in company stock instead of cash.

Does this Imunon (IMNN) Form 4 involve any reported stock sales by Michael H. Tardugno?

No sales are reported. The Form 4 shows a grant/acquisition of 7,147 shares of common stock and a separate holding entry for 4,622 shares in an IRA, with no sale transactions disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/17/2026 - 04:21 PM Accepted by SEC EDGAR 08/17/2026 - 04:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tardugno Michael H

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Chairman of Board

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		A		7,147(1)	A	$1.65	82,504	D
Common Stock								4,622	I	Held by IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock granted in lieu of cash for base salary

	/s/ Susan Eylward, Attorney-in-Fact for Michael Tardugno	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)